Smoking cessation in patients with urothelial carcinoma has significant and positive effects on quality of life, disease coping, and clinical outcomes.

Smoking cessation in patients with urothelial carcinoma has significant and positive effects on quality of life, disease coping, and clinical outcomes. - RUELS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037523

Enrollment

300

Registered

2025-10-23

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Intervention (Structured Training Program)** Participation in a behaviorally-based, certified smoking cessation program (“Smoke-Free in 6 Weeks”) offered by the Suchtberatung Singen counsel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Histologically confirmed urothelial carcinoma stages T1–T3, N0–N1, M0 - Active nicotine consumption, defined as =5 cigarettes per day - Planned or performed surgical treatment, e.g., transurethral resection of a bladder tumor (TUR-B) or radical cystectomy - Age =18 years - Written informed consent to participate in the study after being informed according to ethical guidelines

Exclusion criteria

Exclusion criteria: - Exclusion from participation or lack of capacity to consent - Presence of a severe physical or mental illness that significantly limits participation in smoking cessation or the conduct of the study - Non-smokers or former smokers who have been abstinent from nicotine for more than 12 months

Design outcomes

Primary

Measure	Time frame
Occurrence of tumor recurrence in patients with successful nicotine cessation compared to patients without nicotine cessation, measured at three time points (6 weeks, 6 months, and 12 months after completion of the cessation program).	—

Secondary

Measure	Time frame
• Change in quality of life measured with a validated QoL instrument (e.g., EORTC QLQ-C30) at the specified time points. • Change in disease-related coping strategies (e.g., assessed using the "FKV – Questionnaire for Coping with Illness"). • Success rate of nicotine abstinence in the two intervention groups over a period of 12 months.	—

Countries

Germany

Contacts

Public ContactJörg Minner

Urologische Klinik am Hegau-Bodensee Klinikum Singen

joerg.minner@glkn.de+497731892900

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026